The response evaluation of adjacent DCIS is highly relevant, as NST containing HER2-blockade frequently results in pCR of HER2-positive IBC, but the presence of extensive, clinically detectable DCIS pre-NST often precludes performing BCS. Here, ERBB2 is linked to inflammatory breast carcinoma.